Endocrine Symposium focuses on Type 1 diabetes

You will learn:
• Progress in the understanding of the genetic and autoimmune factors involved in the pathogenesis of type 1 diabetes, as well as the paracrine interactions between alpha and beta cells of the pancreatic islets, has opened the way for development of new and targeted therapies for treatment and prevention of the disease
• In people with type 1 diabetes, fluctuations of plasma glucose throughout the day may be associated with periods of hyper- and hypoglycaemia, and, when variability is erratic and unpredictable, it complicates treatment with exogenous insulin and efforts to maintain euglycaemia
• Long-term visit-to-visit fluctuations in HbA1c measured over months to years have been shown to correlate with microvascular complications, diabetic kidney disease, cardiovascular autonomic neuropathy, macrovascular complications and all-cause mortality in diabetic patients
• The primary goal for effective and safe glucose control is to increase the time in range (3.9 to 10.0mmol/l) while reducing the time below range, with a target for time in range of >70% in a 24-hour period
• Insulin degludec is an ultra-long-acting basal insulin with a flat pharmacokinetic profile at steady state, resulting in low fluctuations in glucose lowering activity across each dosing interval. Less glucose variability is associated with a significantly lower risk of hypoglycaemic events, including nocturnal and severe symptomatic hypoglycaemia
• In order to achieve HbA1c targets and improve clinical outcomes in patients with diabetes, it is imperative to not only manage fasting plasma glucose (FPG), but to reduce and control postprandial glucose (PPG) excursions as well
• Fast-acting IAsp (faster aspart) is a modified formulation of IAsp with a faster onset of action, shorter time to 50% maximum concentration, shorter time to maximum concentration, and faster time to offset, with consequent improvement in PPG control and lower risk of postprandial hypoglycaemia.